Home > Insider Trading > Filing (0001562180-22-001435)

Filing Details

Accession Number:: 0001562180-22-001435
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2022-02-11 21:41:28
Reporting Period:: 2020-06-15

Accepted Time:: 2022-02-11 21:41:28
Original Submission Date:: 2020-06-17
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1689813	Biohaven Pharmaceutical Holding Co Ltd.	BHVN	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1704234	Declan Doogan	C/O Biohaven Pharmaceuticals, Inc. 215 Church Street New Haven CT 06510		No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Shares	Disposition	2020-06-15	2,464	$67.83	726,002	No	4	S	Indirect	By the Declan Doogan 2014 Trust
Common Shares	Disposition	2020-06-15	13,334	$68.15	333,912	No	4	S	Direct
Common Shares	Disposition	2020-06-16	15,508	$68.58	676,002	No	4	S	Indirect	By the Declan Doogan 2014 Trust
Common Shares	Disposition	2020-06-16	10,000	$68.97	323,912	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	By the Declan Doogan 2014 Trust
No	4	S	Direct
No	4	S	Indirect	By the Declan Doogan 2014 Trust
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $67.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.86 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $68.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.77 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.